In a nutshell This study wanted to find out if patients with melanoma who had immune system side effects after treatment with nivolumab (Opdivo) had better outcomes than patients without side effects. The study found that the patients who had side effects from using nivolumab ended up with better responses to treatment and...
Read More
In a nutshell This study investigated whether levels of S100B and lactate dehydrogenase (LDH) in patients with melanoma treated with immunotherapy has any relationship to survival. The study found that increased levels of S100B and LDH were associated with reduced survival in patients with melanoma treated with certain immunotherapies. Some background...
Read More
In a nutshell This study investigated if histological regression (HR – replacement of cancer tumor cells by inflammation) can be used to predict the course of disease (prognosis) in patients with stage III (advanced) melanoma. The study found that histological regression was associated with a better prognosis in patients with stage III...
Read More
In a nutshell This study investigated if sentinel lymph node (SLN) status was linked to Breslow thickness in understanding the prognosis of melanoma (a type of skin cancer). The study concluded that SLN status was not linked to Breslow thickness (BT) for melanoma prognosis. Some background Sentinel lymph nodes...
Read MoreIn a nutshell This study investigated the impact of the time between diagnosis and sentinel lymph node biopsy (SLNB) in melanoma outcomes. Researchers suggested that no negative effects are associated with delayed SLNB. Some background SLNB is a procedure used to detect lymph node metastasis (spread disease) in melanoma patients. The...
Read MoreIn a nutshell This study analyzed outcomes in advanced skin cancer patients who stopped their treatment of nivolumab (Opdivo) and ipilimumab (Yervoy) due to side effects. This study concluded that many patients still benefit from the combination even after stopping treatment. Some background...
Read More
Video information: As part of our coverage from the 2017 American Society of Clinical Oncology annual meeting, Dr. Ryan Sullivan from Massachusetts General Hospital Cancer Center and Harvard Medical School provides a positive update for melanoma patients. Dr. Sullivan shares positive news related to PD-1 inhibitors and other promising advancements...
Read MoreIn a nutshell This study investigated the effectiveness of talimogene laherparepvec (Imlygic; T-VEC) with ipilimumab (Yervoy) in the treatment of inoperable stage 3 or 4 melanoma. Researchers concluded that this combination improves melanoma outcomes, with manageable side effects. Some background Immunotherapy has become an...
Read More
In a nutshell This study reviewed the effectiveness and safety of combined treatment with BRAF and MEK inhibitors in patients with advanced melanoma. Researchers suggested that combined treatment of BRAF and MEK inhibitors was associated with better responses than other treatments. Some background Some melanoma patients have a mutation...
Read MoreIn a nutshell This trial aims to test the safety and effectiveness of combined treatment with dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with inoperable advanced BRAF mutated melanoma. The main outcome to be measured will be the time to disease progression, response rates, and the number of negative side effects. The...
Read MoreIn a nutshell This trial aims to test safety and effectiveness of the combined treatment with pembrolizumab (Keytruda) and vemurafenib (Zelboraf) in patients with stage 3 or 4 melanoma. The main outcome to be measured will be the response of the tumors to the treatment. This trial is recruiting in Pittsburgh, Pennsylvania (US). The details Tumors...
Read MoreIn a nutshell The authors investigated the correlation between the level of PD-1, an important protein in immune system, and clinical response of melanoma patients treated with anti-PD1 therapy. The authors concluded that the level of PD-1 was significantly associated with clinical response in metastatic melanoma patients receiving anti-PD1...
Read More
